6533b834fe1ef96bd129e154

RESEARCH PRODUCT

Pefloxacin in the Antibacterial Treatment of Immunodepressed Patients

A. La SalaR. CarboneR. PerriconeA. SgalambroMario CarotenutoF. DammaccoA. CajozzoS. MancusoM. Grana

subject

Adult0301 basic medicinemedicine.medical_specialty030106 microbiologyAIDS-related complexMalignancyPefloxacin03 medical and health sciencesGastrointestinal disturbances0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)NeoplasmsInternal medicineImmune ToleranceHumansMulticenter Studies as TopicMedicinePharmacology (medical)Fever of unknown originAgedAged 80 and overPharmacologyAcquired Immunodeficiency Syndromebusiness.industryBacterial InfectionsMiddle Agedmedicine.diseaseRashPefloxacinTreatment efficacyInfectious DiseasesOncology030220 oncology & carcinogenesismedicine.symptombusinessmedicine.drug

description

Pefloxacin 800 to 1200 mg daily was given for 3 to 20 days, orally or intravenously, to 84 immunocompromised patients. Five patients dropped out because of side effects and 2 for other causes. Treatment efficacy was evaluated in 77 patients, 43 men and 34 women, aged 18 to 80 years. Immunodepression resulted from malignancy in 46 patients, LAS/ARC or AIDS in 28, and from unknown causes in 3. Fifty-eight patients had documented infections (respiratory-tract infections 29, urinary-tract infections 13, septicemia 10, other 6) and 19 had a fever of unknown origin (FUO). Cure or significant improvement of symptoms was achieved in 81% of patients with documented infections and in 74% of patients with FUO. Side effects (mainly gastrointestinal disturbances and skin rash) occurred in 7 patients (8.2%), including dropouts. These results suggest that pefloxacin may be useful for the antibacterial treatment of immunodepressed patients.

yearjournalcountryeditionlanguage
1990-06-01Journal of Chemotherapy
https://doi.org/10.1080/1120009x.1990.11739016